Brief: Dawnrays Pharmaceutical (Holdings) Says HY Revenue Rmb649.9 Million
25/08/2023 16:02
Aug 25 (Reuters) - Dawnrays Pharmaceutical (Holdings)
Ltd 2348.HK :
* HY REVENUE RMB649.9 MILLION VERSUS RMB623.5 MILLION
* HY PROFIT FOR ATTRIBUTABLE RMB255.9 MILLION VERSUS
RMB171.7
MILLION
Source text for Eikon: ID:nHKSc4PrhY
Further company coverage: 2348.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dawnrays Pharmaceutical (Holdings)
See all newsBrief: Dawnrays Pharmaceutical Says Suzhou Dawnrays Commits To Invest Up To RMB100 Mln In Partnership
Brief: Dawnrays Pharmaceutical (Holdings) Final Dividend Of Hk$0.048 Per Share
Brief: Dawnrays Pharmaceutical Reports HY Net Income Attributable Of RMB104.6 MLN
Brief: Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Appoints Yu Liwei To Act As CEO